File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1093/ndt/gfu411
- Scopus: eid_2-s2.0-84960093606
- PMID: 25637638
- WOS: WOS:000371521400006
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Diabetic Nephropathy: landmark clinical trials and tribulations
Title | Diabetic Nephropathy: landmark clinical trials and tribulations |
---|---|
Authors | |
Keywords | clinical trials diabetic nephropathy humans |
Issue Date | 2015 |
Publisher | Oxford University Press. The Journal's web site is located at http://ndt.oxfordjournals.org/ |
Citation | Nephrology Dialysis Transplantation, 2015, v. 31 n. 3, p. 359-368 How to Cite? |
Abstract | Diabetic nephropathy remains the most common cause of end-stage renal disease worldwide. The current standard of therapy for diabetic nephropathy involves stringent blood pressure control via blockade of the renin–angiotensin system and control of hyperglycemia. Despite these strategies, diabetic nephropathy is still seen to progress relentlessly. A pressing need for novel therapeutic agents has fueled endless basic science research projects and clinical trials in the quest for a more specific therapy. Throughout the process, only a handful of ancillary agents have shown experimental promise and even fewer have demonstrated an impact in human trials. This review article aims to summarize the available data from landmark studies for the main therapeutic approaches investigated. |
Persistent Identifier | http://hdl.handle.net/10722/214359 |
ISSN | 2023 Impact Factor: 4.8 2023 SCImago Journal Rankings: 1.414 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | CHAN, GCW | - |
dc.contributor.author | Tang, SCW | - |
dc.date.accessioned | 2015-08-21T11:18:38Z | - |
dc.date.available | 2015-08-21T11:18:38Z | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Nephrology Dialysis Transplantation, 2015, v. 31 n. 3, p. 359-368 | - |
dc.identifier.issn | 0931-0509 | - |
dc.identifier.uri | http://hdl.handle.net/10722/214359 | - |
dc.description.abstract | Diabetic nephropathy remains the most common cause of end-stage renal disease worldwide. The current standard of therapy for diabetic nephropathy involves stringent blood pressure control via blockade of the renin–angiotensin system and control of hyperglycemia. Despite these strategies, diabetic nephropathy is still seen to progress relentlessly. A pressing need for novel therapeutic agents has fueled endless basic science research projects and clinical trials in the quest for a more specific therapy. Throughout the process, only a handful of ancillary agents have shown experimental promise and even fewer have demonstrated an impact in human trials. This review article aims to summarize the available data from landmark studies for the main therapeutic approaches investigated. | - |
dc.language | eng | - |
dc.publisher | Oxford University Press. The Journal's web site is located at http://ndt.oxfordjournals.org/ | - |
dc.relation.ispartof | Nephrology Dialysis Transplantation | - |
dc.subject | clinical trials | - |
dc.subject | diabetic nephropathy | - |
dc.subject | humans | - |
dc.title | Diabetic Nephropathy: landmark clinical trials and tribulations | - |
dc.type | Article | - |
dc.identifier.email | Tang, SCW: scwtang@hku.hk | - |
dc.identifier.authority | Tang, SCW=rp00480 | - |
dc.identifier.doi | 10.1093/ndt/gfu411 | - |
dc.identifier.pmid | 25637638 | - |
dc.identifier.scopus | eid_2-s2.0-84960093606 | - |
dc.identifier.hkuros | 248223 | - |
dc.identifier.hkuros | 263309 | - |
dc.identifier.volume | 31 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 359 | - |
dc.identifier.epage | 368 | - |
dc.identifier.isi | WOS:000371521400006 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 0931-0509 | - |